![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results
February 26, 2015 07:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer
February 19, 2015 08:00 ET
|
Merrimack Pharmaceuticals
Trial is recruiting biomarker-selected patients previously treated with two lines of therapy for locally advanced or metastatic disease
Merrimack's first study to prospectively select patients...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
February 12, 2015 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2014 Investor Conference Call and...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
January 22, 2015 17:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division....
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
January 20, 2015 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
January 08, 2015 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that additional analyses from the Phase 3 NAPOLI-1 study of MM-398 (nanoliposomal...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
January 07, 2015 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 33rd Annual...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors
December 17, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Russell T. Ray to its Board of Directors, effective January 1,...
![Merrimack logo](/news-release/logo/279059/0/279059.jpg?lastModified=12%2F09%2F2016%2023%3A02%3A16&size=2)
Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
December 12, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced data from multiple presentations at the 2014 San Antonio Breast Cancer Symposium in...
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research
December 04, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that Cancer Research has published the paper "Preclinical Activity of Nanoliposomal...